Per accedir als documents amb el text complet, si us plau, seguiu el següent enllaç: http://hdl.handle.net/2445/130991
dc.contributor.author | Navarro Ponz, Alfons |
---|---|
dc.contributor.author | Moisés, Jorge |
dc.contributor.author | Santasusagna, Sandra |
dc.contributor.author | Marrades Sicart, Ramon Ma. |
dc.contributor.author | Viñolas Segarra, Núria |
dc.contributor.author | Castellano, Joan Josep |
dc.contributor.author | Canals, Jordi |
dc.contributor.author | Muñoz García, Carmen |
dc.contributor.author | Ramirez, José |
dc.contributor.author | Molins López-Rodó, Laureano |
dc.contributor.author | Monzó Planella, Mariano |
dc.date | 2019-03-27T18:41:54Z |
dc.date | 2019-03-27T18:41:54Z |
dc.date | 2019-02-28 |
dc.date | 2019-03-27T18:41:54Z |
dc.identifier | 1471-2466 |
dc.identifier | 689307 |
dc.identifier | 30819158 |
dc.identifier.uri | http://hdl.handle.net/2445/130991 |
dc.description | Background HOTTIP, a long non-coding RNA located in the HOXA cluster, plays a role in the patterning of tissues with mesodermal components, including the lung. Overexpression of HOXA genes, including HOTTIP, has been associated with a more aggressive phenotype in several cancers. However, the prognostic impact of HOTTIP has not yet been explored in non-small-cell lung cancer (NSCLC). We have correlated HOTTIP expression with time to relapse (TTR) and overall survival (OS) in early-stage NSCLC patients. Methods Ninety-nine early-stage NSCLC patients who underwent surgical resection in our center from June 2007 to November 2013 were included in the study. Mean age was 66; 77.8% were males; 73.7% had stage I disease; and 55.5% had adenocarcinoma. A validation data set comprised stage I-II patients from The Cancer Genome Atlas (TCGA) Research Network. Results HOTTIP was expressed in all tumor samples and was overexpressed in squamous cell carcinoma (p = 0.007) and in smokers (p = 0.018). Patients with high levels of HOTTIP had shorter TTR (78.3 vs 58 months; p = 0.048) and shorter OS (81.2 vs 61 months; p = 0.023) than those with low levels. In the multivariate analysis, HOTTIP emerged as an independent prognostic marker for TTR (OR: 2.05, 95%CI: 1-4.2; p = 0.05), and for OS (OR: 2.31, 95%CI: 1.04-5.1; p = 0.04). HOTTIP was validated as a prognostic marker for OS in the TCGA adenocarcinoma cohort (p = 0.025). Moreover, we identified a 1203-mRNA and a 61-miRNA signature that correlated with HOTTIP expression. Conclusions The lncRNA HOTTIP can be considered a prognostic biomarker in early-stage NSCLC. |
dc.format | 9 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | BioMed Central |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1186/s12890-019-0816-8 |
dc.relation | BMC Pulmonary Medicine, 2019, vol. 19, num. 1, p. 55-63 |
dc.relation | https://doi.org/10.1186/s12890-019-0816-8 |
dc.rights | cc-by (c) Navarro Ponz, Alfons et al., 2019 |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Càncer de pulmó |
dc.subject | RNA |
dc.subject | Lung cancer |
dc.subject | RNA |
dc.title | Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |